Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma

MLA

Zoe B. Ciantra, et al. “Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma.” JAMA Oncology, vol. 6, Oct. 2020, p. 1563. EBSCOhost, https://doi.org/10.1001/jamaoncol.2020.2955.

APA

Zoe B. Ciantra, Shana Criscitiello, Jason I. Kass, Jochen H. Lorch, Roy B. Tishler, Kai W. Wucherpfennig, Glenn J. Hanna, Nicole G. Chau, Adrienne M. Luoma, Ravindra Uppaluri, Danielle N. Margalit, Heather A. Jacene, Donald J. Annino, Anupam M. Desai, Bhupendra Rawal, Brendan Ross, Robert I. Haddad, Vickie Y. Jo, Jason L. Weirather, … Scott J. Rodig. (2020). Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. JAMA Oncology, 6, 1563. https://doi.org/10.1001/jamaoncol.2020.2955

Chicago

Zoe B. Ciantra, Shana Criscitiello, Jason I. Kass, Jochen H. Lorch, Roy B. Tishler, Kai W. Wucherpfennig, Glenn J. Hanna, et al. 2020. “Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma.” JAMA Oncology 6 (October): 1563. doi:10.1001/jamaoncol.2020.2955.